Introduction: The amount of platelets considered a therapeutic dose remains controversial and undecided. The multiple studies show that a lower platelet dose for prophylactic transfusions was not inferior to the standard dose.9 Method: 61 patients with haemato-oncological patients with severe thrombocytopenia underwent platelet transfusion with group specific single donor apheresis platelets of low dose. We define 1.1 to 1.9 × 1011 platelets/ transfusion as low dose. The successful platelet transfusion can be assessed by calculating corrected count Increment (CCI) and percentage platelet recovery (PPR) at 1 hour and 24 hours post transfusion which indicate the functional platelets in circulation. Results: The mean ± SD & range of t CCI at 1 hour were 12265.28 ± 3531.09 (SD) & 3916 to 21677 and after 24 hours 8310.43 ± 2698.73 (SD) & 1350 to 16722 respectively. In the CCI at 24 hours it was observe, d that there were 11.48% (7) cases having the CCI below 4500 and 88.52% (54) cases were belonged to the groups of 4500 & above. Only 16.39% (10) cases were having PPR of below 30% and 83.61% (51) cases had the PPR of 30% & above at 1 hour. PPR at 24 hours showed that only 16.39% (10) cases were having PPR of below 20% and 83.61% (51) cases had the PPR of 21% & above. Conclusion: Low dose platelet transfusion (1.1-1.9× 1011 platelets / dose),is good enough to attain therapeutic response in terms of CCI and PPR. Thus both hazards and cost related to transfusion can be minimized.
